Lv428
730 积分 2025-08-21 加入
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
1天前
已完结
Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants
5天前
已完结
Multifocal papillary thyroid carcinoma with RET p.V804M, EML4-ALK fusion, and BRAF V600E positivity
5天前
已完结
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma
1个月前
已完结
甲状腺未分化癌诊疗专家共识(2023版)
1个月前
已关闭
Cytomorphologic and Histologic Correlation on TERT Promotor Mutations in Thyroid Tumors: One Institutional Experience
1个月前
已关闭
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
1个月前
已完结
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
1个月前
已完结
Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib
1个月前
已完结
皖公网安备34019202002308
